Cardiovascular effects of l-glutamate microinjection in the supraoptic nucleus of unanaesthetized rats

We report on the cardiovascular effects of l-glutamate ( l-glu) microinjection in the hypothalamic supraoptic nucleus (SON) as well as possible receptor and mechanisms involved. Microinjection of l-glu in 100 nL in the SON caused dose-related pressor and bradycardic responses in unanesthetized rats....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuropharmacology 2007-05, Vol.52 (6), p.1378-1384
Hauptverfasser: Busnardo, C., Tavares, R.F., Antunes-Rodrigues, J., Corrêa, F.M.A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We report on the cardiovascular effects of l-glutamate ( l-glu) microinjection in the hypothalamic supraoptic nucleus (SON) as well as possible receptor and mechanisms involved. Microinjection of l-glu in 100 nL in the SON caused dose-related pressor and bradycardic responses in unanesthetized rats. Responses were markedly reduced in urethane-anesthetized rats. The response to l-glu 10 nmol was blocked by local pretreatment with 2 nmol of the non-NMDA-receptors antagonist NBQX and not affected by 2 nmol of the selective NMDA-receptor antagonist LY 235959, suggesting that non-NMDA receptors mediate these responses. The pressor and bradycardic response to l-glu was potentiated by intravenous pretreatment with the ganglion blocker pentolinium and was blocked by intravenous pretreatment with the V 1-vasopressin receptor antagonist dTyr(CH 2) 5(Me)AVP, suggesting involvement of circulating vasopressin in this response. Additionally l-glu microinjection into the SON increased plasma vasopressin levels (control: 1.3 ± 0.2 pg/mL, n = 6; l-glu: 14.7 ± 2.3 pg/mL, n = 6). In conclusion the results suggest that pressor responses to SON microinjection of l-glu are caused by activation of non-NMDA glutamate receptors and mediated by vasopressin release into systemic circulation.
ISSN:0028-3908
1873-7064
DOI:10.1016/j.neuropharm.2007.01.011